Pharmacokinetics and systemic endocrine effects of the phyto‐oestrogen 8‐prenylnaringenin after single oral doses to postmenopausal women
- 21 April 2006
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 62 (3), 288-296
- https://doi.org/10.1111/j.1365-2125.2006.02656.x
Abstract
Pre-clinical data suggest that the racemic phyto-oestrogen 8-prenylnaringenin (8-PN) may have beneficial effects in postmenopausal women and may become an alternative to classical hormone replacement therapy (HRT) treatment regimes. The aim of this study was to investigate the pharmacokinetics, endocrine effects and tolerability of chemically synthesized 8-PN in postmenopausal women. The study was performed using a randomized, double-blind, placebo-controlled, dose-escalation design with three groups of eight healthy postmenopausal women. In each group six subjects received 8-PN and two subjects placebo. 8-PN was given orally in doses of 50, 250 or 750 mg. Drug concentrations in serum, urine and faeces were measured up to 48 h and follicle-stimulating hormone/luteinizing hormone (LH) concentrations up to 24 h. All treatments were well tolerated and associated with a low incidence of (drug unrelated) adverse events. Serum concentrations of free 8-PN showed rapid drug absorption and secondary peaks suggestive of marked enterohepatic recirculation. Independent of the treatment group, approximately 30% of the dose was recovered in excreta as free compound or conjugates over the 48-h observation period. The first C(max) and AUC(0-48 h) showed dose linearity with ratios of 1 : 4.5 : 13.6 (C(max)) and 1 : 5.2 : 17.1 (AUC). The750- mg dose decreased LH concentrations by 16.7% (95% confidence interval 0.5, 30.2). Single oral doses of up to 750 mg 8-PN were well tolerated by postmenopausal women. The pharmacokinetic profile of 8-PN was characterized by rapid and probably complete enteral absorption, high metabolic stability, pronounced enterohepatic recirculation and tight dose linearity. The decrease in LH serum concentrations found after the highest dose demonstrates the ability of 8-PN to exert systemic endocrine effects in postmenopausal women.Keywords
This publication has 32 references indexed in Scilit:
- Development of a Radioimmunoassay for the Quantitative Determination of 8-Prenylnaringenin in Biological MatricesJournal of Agricultural and Food Chemistry, 2005
- Phytoestrogens for Treatment of Menopausal Symptoms: A Systematic ReviewObstetrics & Gynecology, 2004
- 8‐prenylnaringenin, a novel phytoestrogen, inhibits angiogenesis in vitro and in vivoJournal of Cellular Physiology, 2003
- Breast cancer and hormone-replacement therapy: the Million Women StudyThe Lancet, 2003
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- 8-Prenylnaringenin, the phytoestrogen in hops and beer, upregulates the function of the E-cadherin/catenin complex in human mammary carcinoma cellsEuropean Journal of Cell Biology, 2001
- Prenylflavonoids: A New Class of Non-Steroidal Phytoestrogen (Part 1). Isolation of 8-Isopentenylnaringenin and an Initial Study on its Structure-Activity RelationshipPlanta Medica, 1998
- PLASMA LEVELS OF OESTRONE, OESTRADIOL AND GONADOTROPHINS IN POSTMENOPAUSAL WOMEN AFTER ORAL AND VAGINAL ADMINISTRATION OF CONJUGATED EQUINE OESTROGENS (PREMARIN)BJOG: An International Journal of Obstetrics and Gynaecology, 1978